

VIENNA

eular²⁴

EUROPEAN
CONGRESS OF
RHEUMATOLOGY

VIENNA
12 – 15 JUNE

INDUSTRY PROGRAMME & EXHIBITORS BOOKLET

Status as of 13 May 2024

congress.eular.org

INDUSTRY PROGRAMME & EXHIBITORS BOOKLET

Since its introduction in 2000, the European Congress of Rheumatology has become the primary platform for exchanging scientific and clinical information in Europe. It is a highly recognised event which facilitates interaction between expert medical doctors and scientists, people with arthritis/rheumatism, health professionals and representatives of the healthcare industry each year.

EULAR, the European Alliance of Associations for Rheumatology is proud to present to you the Satellite Symposia and Consult the Expert sessions organised by our industry partners as well as a comprehensive list of exhibitors showcasing at EULAR 2024.



INDUSTRY PROGRAMME

PROGRAMME OVERVIEW	5
WEDNESDAY	9
THURSDAY	21
FRIDAY	41

EXHIBITORS

INDUSTRY PARTNERS	53
WHERE YOU CAN FIND OUR INDUSTRY PARTNERS AT THE CONGRESS___	54
INDUSTRY PARTNERS DESCRIPTION	56


Please join us for the following sessions:

What makes deucravacitinib *TYK*?

Thursday, 13 June 2024 | 08:15 - 09:30 | Room A8.2

Featuring presentations by:

- Prof. Josef Smolen - Chair
- Prof. Hendrik Schulze-Koops
- Prof. Joan Merrill
- Prof. Alberto Cauli



Followed by


Live Q&A Session

CAR T Therapy: Bringing a Decade of Successful Experience to Patients With Autoimmune Diseases

Thursday, 13 June 2024 | 17:30 – 18:45 | Room Strauss 2

Featuring presentations by:

- Prof. Anca Askanase
- Prof. Ricardo Grieshaber-Bouyer
(featuring a patient interview)
- Dr. Ashley Koegel




Followed by

Live Q&A Session

PROGRAMME OVERVIEW

Status as of 13 May 2024



WEDNESDAY

12 JUNE 2024

Status as of 13 May 2024

15:45–16:15

GSK

New Paths, New Crossroads:
Seeing into Systemic
Sclerosis

18:30–19:45

ABBVIE

The Great Quest for Disease
Control in PsA

ALFASIGMA

JAK inhibitors in practice:
unlocking the potential in the
real world of RA

ASTRAZENECA

Remission in SLE: paving the
way to improved patient care

GSK

Advancing lupus care: acting
early to reduce the risk of
organ damage progression

JOHNSON & JOHNSON

Charting the long course of
psoriatic arthritis

NOVARTIS

The Great Scientific Debate:
IL-1 β Inhibition vs IL-1
Receptor Blockade in AOSD

SOBI

Crystallising Options:
Overcoming Challenges in
the Care of Severe Gout

UCB

A Visit to the RFuture:
Maximising Impact by
Personalised Treatment in RA

THURSDAY

13 JUNE 2024

Status as of 13 May 2024

08:15–09:30

BMS

What makes deucravacitinib TYK?

BOEHRINGER INGELHEIM

Systemic sclerosis:
addressing the challenges

ELI LILLY

Dispelling common myths in
Spondyloarthritis

GSK

EGPA Care Reimagined:
Biologics through the lens of
RWE

MERCK

Toll-Like Receptors: an
evolving story in lupus

NOVARTIS

Revealing New Layers:
How Targeting IL-17A is
Shaping Rheumatic and
Musculoskeletal Disease
Management

PFIZER

Expert perspectives: patient
selection for tofacitinib in RA

09:45–10:15

GSK

Seizing the Window of
Opportunity in Lupus: How to
Achieve Disease Modification

JOHNSON & JOHNSON

With a little help from my
peers: challenging PsA cases
in daily practice

SOBI

Macrophage Activation
Syndrome in Still's
Disease – Current State and
Future Horizons of Patient
Management

15:00–15:30

GSK

Practical considerations when
advancing lupus care

NOVARTIS

FMF: the role of canakinumab
in the treatment paradigm

17:30–18:45

ABBVIE

All Aboard!: Choosing the
Right Tracks to Accelerate
Patients With RA and SpA
Toward Their Goals

ASTRAZENECA

The mission for remission:
what is now possible for our
patients?

BMS

CAR T therapy - bringing
a decade of successful
experience to patients with
Autoimmune diseases

BOEHRINGER INGELHEIM

Tackling interstitial lung
disease in patients with
systemic sclerosis or
rheumatoid arthritis

CSL VIFOR

Excellence in ANCA-
associated vasculitis (AAV)
– from diagnosis to optimal
care

JOHNSON & JOHNSON

The cycle of inflammation:
IL-23 across psoriatic disease

PFIZER

Expert perspectives: cross-
speciality applications of
tofacitinib in AS and UC

UCB

Time to Revolutionise
Clinical Practice? Striving for
Resolution of Inflammation
with the Dual Inhibition of
IL-17A and IL-17F in PsA
and axSpA

FRIDAY
14 JUNE 2023

Status as of 13 May 2024

08:15–09:30

CABALETTA BIO

Immune Reset: The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease

GSK

EGPA: Exploring the emerging evidence

KYVERNA

Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond

MEDAC

Optimizing methotrexate – how to achieve maximum results with the anchor drug of RA therapy

OTSUKA

What's new in Lupus Nephritis: from guidelines to real-world practices

09:45–10:15

ASTRAZENECA

Achieving disease control across organ systems – expert perspectives from the real world

UCB

Unlock Your Digital Impact: Social Media Master Class

GSK

The power of prevention: Why herpes zoster vaccination matters in patients with rheumatic diseases

17:30–18:45

AMGEN

What's New in IgG4-Related Disease and Where Do We Go Next

ASTRAZENECA

Rheumatology meets pulmonology: holistic perspectives for EGPA

SANOFI

Unveiling the Clinical Canvas: Navigating Unmet Needs in Polymyalgia Rheumatica

INDUSTRY
PROGRAMME
ON
WEDNESDAY
12 JUNE 2024

Status as of 13 May 2024

15:45–16:15 CONSULT THE EXPERT 1

CONSULT THE EXPERT

GSK

NEW PATHS, NEW CROSSROADS: SEEING INTO SYSTEMIC SCLEROSIS**LEARNING OBJECTIVE(S):**

- | To update delegates on the latest findings in the immunopathogenesis of SSc and SSc-ILD, focusing on the inflammatory and fibrotic processes, and learn from the interactive debate that results.
- | Speakers will proactively interact with the audience after the introduction of each new topic in order to encourage robust scientific exchange between the speakers and the audience.

Prof. CHRISTOPHER DENTON

Prof. Dr. JÖRG DISTLER

15:45 New Paths, New Crossroads: Seeing into Systemic Sclerosis (C. Denton, J. Distler)

18:30–19:45 SESSION ROOM C7

SATELLITE SYMPOSIUM

ABBVIE**THE GREAT QUEST FOR DISEASE CONTROL IN PSA****LEARNING OBJECTIVE(S):**

- | Outline the pathogenesis and important signaling pathways of PsA leading to multiple disease manifestations.
- | Debate the importance of using stringent disease targets as a treatment goal for patients with PsA, and their correlation with patient-reported outcomes.
- | Compare and contrast the different treatment options for PsA in the context of these targets of disease control.

Prof. IAIN MCINNES

Prof. LIHI EDER

Prof. LAURA COATES

18:30	Elements of a Quest and Setting the Stage in PsA (I. McInnes)
18:40	How should we consider the patient's clinical manifestations? (L. Coates, L. Eder)
18:50	How do we choose a stringent disease target? (L. Coates, L. Eder)
19:10	How do we better understand the impact on the patient (L. Coates, L. Eder)
19:35	How might immunophenotypes guide treatment choice in the future? (L. Coates, L. Eder)
19:40	What Have We Learned From Our Quest? (I. McInnes)

18:30–19:45 STRAUSS 3

SATELLITE SYMPOSIUM

UCB**A VISIT TO THE RFUTURE: MAXIMISING IMPACT BY PERSONALISED TREATMENT IN RA****LEARNING OBJECTIVE(S):**

- | To deep dive into the impact of high rheumatoid factor in patients with RA and its role in maximising outcomes.
- | To explore current perspectives on harnessing personalised and AI-enhanced approaches to optimise treatment success for patients with RA.

Prof. YOSHIYA TANAKA

Prof. JAMES GALLOWAY

Prof. PETER C. TAYLOR

Prof. Dr. THOMAS HÜGLE

-
- | | |
|-------|--|
| 18:30 | Welcome and Introduction (Y. Tanaka) |
| 18:35 | Simple Tools to Understand More: The Role of Rheumatoid Factor from Early Phases of RA to Long-Term Management (J. Galloway) |
| 18:55 | So Many Options, Yet Limited Personalisation. How Can We Maximise Disease Control? (P. Taylor) |
| 19:15 | AI Models for RA – What Should We Expect Next? (T. Hügle) |
| 19:30 | Question and Answer Discussion (Y. Tanaka, J. Galloway, P. Taylor, T. Hügle) |

THE GREAT

SCIENTIFIC

DEBATE

**IL-1 β
INHIBITION**

VS.

**IL-1 RECEPTOR
BLOCKADE**

IN AOSD

**12/06/24
18:30–19:45 CEST
ROOM A8.1**

AE, adverse event; AOSD, adult-onset Still's disease; IL, interleukin.

Please scan the QR code to access the full ILARIS (canakinumab) Summary of Product Characteristics (SmPC).

This is a promotional event funded and organized by Novartis.

This event is intended for healthcare professionals (HCPs) only. Only approved products may be prescribed, in accordance with their approved indications. Prescribing information may vary from country to country. Physicians should refer to the Summary of Product Characteristics (SmPC) or product information approved in their local country. Please consult your local AE reporting guidelines.



 **NOVARTIS** | Reimagining Medicine

Novartis Pharma AG
CH-4002 Basel Switzerland

©2024 Novartis

05/24

440513

For healthcare professionals only

EULAR European Congress of Rheumatology 2024 Industry Symposia
AstraZeneca-organised and -funded satellite symposium

Remission in SLE: paving the way to improved patient care

Wednesday 12 June 2024 | 18:30–19:45 CEST | Strauss 2

Treat-to-target: a revolutionary approach to clinical management in rheumatology
Professor Josef Smolen (Chair)

Defining treatment goals in SLE: the importance of individual targets
Professor Marta Mosca

Implementing treat-to-target into SLE care: challenges and opportunities
Professor Josef Smolen in conversation with Professor Marta Mosca

Living with lupus: the importance of patient-focused targets
Mrs Jeanette Andersen

From process to practice: implementing recommendations into clinical care
All faculty



Professor Josef Smolen (Chair)
Medical University of Vienna



Professor Marta Mosca
University of Pisa



Mrs Jeanette Andersen
Lupus Europe

This non-promotional symposium is organised and funded by AstraZeneca.
Veeva ID: AT-11517; Date of preparation: May 2024

AstraZeneca 

18:30–19:45 STRAUSS 1

SATELLITE SYMPOSIUM

JOHNSON & JOHNSON**CHARTING THE LONG COURSE OF PSORIATIC ARTHRITIS****LEARNING OBJECTIVE(S):**

- | Explain the importance of early diagnosis and treatment to prevent disease progression and achieve long-term remission in PsA.
- | Understand the potential for PsA disease interception through early diagnosis and biologic treatment, and the role of imaging to evaluate the speed and prognosis of response, in patients with psoriasis at risk of progressing to PsA.
- | Evaluate the clinical evidence when informing decisions on therapy selection and switching, including when to switch and to which drug class, for patients with PsA.

Prof. Dr. CARLO SELMI

Dr. ALEN ZABOTTI

Dr. HELENA MARZO-ORTEGA

Prof. Dr. FRANK BEHRENS

-
- 18:30 Welcome and Introduction (F. Behrens)
 - 18:35 Time is of the essence: can we intercept PsA? (presentation with a patient case) (A. Zabotti)
 - 18:50 Domain game: updates on PsA management (presentation) (H. Marzo-Ortega)
 - 19:05 Panel Discussion (L. Coates, C. Selmi, A. Zabotti, H. Marzo-Ortega, F. Behrens)
 - 19:15 Navigating the treatment landscape: difficult-to-treat PsA (presentation with a patient case) (C. Selmi)
 - 19:30 Question & Answer and Panel Discussion (L. Coates, C. Selmi, A. Zabotti, H. Marzo-Ortega, F. Behrens)
 - 19:40 Closing Remarks (F. Behrens)

18:30–19:45 SESSION ROOM A8.1

SATELLITE SYMPOSIUM

NOVARTIS**THE GREAT SCIENTIFIC DEBATE: IL-1 β INHIBITION VS IL-1 RECEPTOR BLOCKADE IN AOSD****LEARNING OBJECTIVE(S):**

- | The debate the key differentiating points for the use of IL-1 β inhibition and IL-1 receptor blockade in the treatment of adult-onset Still's disease (AOSD).
- | To further understand the role of biologic therapies in the treatment of patients with AOSD.

Prof. PAUL EMERY

Prof. LORENZO DAGNA

Prof. EUGEN FEIST

18:30	Welcome and Introduction (P. Emery)
18:35	Why use IL-1 inhibitors in the management of AOSD? (P. Emery)
18:45	Debate 1: Speed of onset: IL-1 β inhibition vs IL-1 receptor blockade (L. Dagna, E. Feist, P. Emery)
18:58	Debate 2: Long-term efficacy: IL-1 β inhibition vs IL-1 receptor blockade (L. Dagna, E. Feist, P. Emery)
19:11	Debate 3: Safety profile and patient satisfaction: IL-1 β inhibition vs IL-1 receptor blockade (L. Dagna, E. Feist, P. Emery)
19:24	Final summaries (P. Emery, L. Dagna, E. Feist)
19:30	Q&A and meeting close (P. Emery, L. Dagna, E. Feist)

18:30–19:45 STRAUSS 2

SATELLITE SYMPOSIUM

ASTRAZENECA**REMISSION IN SLE: PAVING THE WAY TO IMPROVED PATIENT CARE****LEARNING OBJECTIVE(S):**

- | Explain how treat-to-target (T2T) has become an established management approach in rheumatoid arthritis and other autoimmune diseases and the potential impact this approach could have on SLE care.
- | Reflect on their own routine management of SLE to consider how to implement a T2T approach in clinical practice.
- | Consider how the patient perspective can be integrated into a T2T approach and discuss strategies to optimise treatment and incorporate the patient voice.

Prof. Dr. JOSEF SMOLEN

Prof. MARTA MOSCA

Mrs JEANETTE ANDERSEN

-
- 18:30 Welcome and Introductions (J. Smolen)
 - 18:35 Treat-to-target: a revolutionary approach to clinical management in rheumatology (J. Smolen)
 - 18:45 Defining treatment goals in SLE: the importance of a multi-target approach (M. Mosca)
 - 18:55 Implementing treat-to-target into SLE care: challenges and opportunities (J. Smolen, M. Mosca)
 - 19:10 Living with lupus: the importance of patient-focused targets (J. Andersen)
 - 19:20 From process to practice: implementing recommendations into clinical (J. Smolen, M. Mosca, J. Andersen)
 - 19:40 Summary and close (J. Smolen, M. Mosca, J. Andersen)

18:30–19:45 STOLZ 2

SATELLITE SYMPOSIUM

GSK

ADVANCING LUPUS CARE: ACTING EARLY TO REDUCE THE RISK OF ORGAN DAMAGE PROGRESSION**LEARNING OBJECTIVE(S):**

- | Experts in SLE and LN will discuss ways to help achieve their goals for their patients with lupus and lupus nephritis, such as reducing the risk of organ damage progression and preserving kidney function. Interactive curbside consultations based on real clinical examples will explore how the latest guidelines and recommendations for the management of lupus have re-shaped the treatment paradigm.

Prof. Dr. ANDREA DORIA

Prof. Dr. ANDREAS SCHWARTING

Dr. DAWN CASTER

-
- 18:30 Welcome and Introduction (A. Doria)
 - 18:35 Biologic therapy for SLE: can we reduce the risk of organ damage progression? (A. Schwarting)
 - 18:45 Curbside consultation: the paradigm shift for a patient with non-renal lupus (A. Doria, A. Schwarting, D. Caster)
 - 19:05 Lupus nephritis: acting early to preserve the kidney (D. Caster)
 - 19:15 Curbside consultation: the paradigm shift for patients with lupus nephritis (A. Doria, A. Schwarting, D. Caster)
 - 19:35 Audience Q&A (A. Doria, A. Schwarting, D. Caster)
 - 19:40 Summary and next steps (A. Doria)

18:30–19:45 SESSION ROOM A8.2

SATELLITE SYMPOSIUM

ALFASIGMA**JAK INHIBITORS IN PRACTICE: UNLOCKING THE POTENTIAL IN THE REAL WORLD OF RA****LEARNING OBJECTIVE(S):**

- | Understand the importance of real-world evidence (RWE) and how it can be interpreted for use in clinical decision-making for patients with RA.
- | With a focus on JAK inhibitors, discuss how RWE expands on efficacy/safety data from randomised controlled trials (RCTs) in patients with RA.
- | Explore real-world case studies of patients with RA treated with filgotinib in FILOSOPHY.

Prof. MAYA BUCH

Prof. Dr. GERD R. BURMESTER

Prof. ROBERTO CAPORALI

Prof. CÉCILE GAUJOUX-VIALA

-
- 18:30 Welcome and Introduction (M. Buch)
 - 18:35 Changing perspectives: the value of RWE in RA (G. R. Burmester)
 - 18:50 Interpreting RWE: building on the data so far (C. Gaujoux-Viala)
 - 19:10 FILOSOPHY in practice: translating the evidence to real-life patients (R. Caporali)
 - 19:30 Q&A and meeting close (M. Buch, G. Burmester, R. Caporali, C. Gaujoux-Viala)

18:30–19:45 STOLZ 1

SATELLITE SYMPOSIUM

SOBI

CRYSTALLISING OPTIONS: OVERCOMING CHALLENGES IN THE CARE OF SEVERE GOUT**LEARNING OBJECTIVE(S):**

- | To highlight unmet needs in gout and the importance of screening for comorbidities, risk factors, and of timely referral, and to emphasise the role of patient education, shared decision making and multidisciplinary care in gout.
- | To communicate guideline recommendations on imaging in gout and to inform attendees on the role of imaging in patient education and management of gout as well to illustrate the benefits of these concepts in clinical practice through interactive patient cases.

Prof. Dr. PETER MANDL

Prof. FREDERIC LIOTE

Prof ABHISHEK ABHISHEK

Dr. PUJA KHANNA

-
- | | |
|-------|--|
| 18:30 | Welcome and introduction (P. Mandl) |
| 18:35 | Multi-faceted Care for Patients with Gout (A. Abhishek, F. Liote) |
| 19:05 | Novel Imaging Modalities in Gout (P. Mandl, P. Khanna) |
| 19:35 | Reflecting on the Future of Care for Patients with Gout Q&A Session (P. Mandl) |

INDUSTRY
PROGRAMME
ON
THURSDAY
13 JUNE 2024

Status as of 13 May 2024

08:15–09:30 STRAUSS 1

SATELLITE SYMPOSIUM

PFIZER**EXPERT PERSPECTIVES: PATIENT SELECTION FOR TOFACITINIB
IN RA****LEARNING OBJECTIVE(S):**

- | Highlight the wealth of clinical study data and real-world evidence for tofacitinib, and the value of using these data to help inform appropriate patient selection.
- | Explore the impact of post-marketing surveillance safety data and post hoc analyses on the selection of appropriate patients for treatment with tofacitinib.
- | Using patient cases, explore how the breadth of data for tofacitinib can inform treatment decision-making and optimise outcomes for patients.

Dr. FRANCESCA ROMANA SPINELLI

Prof. JAMES GALLOWAY

Dr. JANET POPE

08:15	Welcome and introduction (F. Spinelli)
08:20	Meet our patients with RA (J. Galloway, J. Pope)
08:25	How key clinical data and real-world evidence can inform appropriate patient selection (J. Galloway, J. Pope)
08:40	How safety considerations can inform patient selection (J. Pope, F. Spinelli)
08:50	Tools that aid patient selection (J. Galloway, J. Pope)
08:55	Audience Q&A (F. Spinelli, J. Galloway, J. Pope)
09:25	Closing remarks (F. Spinelli)

08:15–09:30 SESSION ROOM A8.1

SATELLITE SYMPOSIUM

NOVARTIS**REVEALING NEW LAYERS: HOW TARGETING IL-17A IS SHAPING RHEUMATIC AND MUSCULOSKELETAL DISEASE MANAGEMENT****LEARNING OBJECTIVE(S):**

- | Review how the understanding of the IL-17 pathway has advanced the treatment and management of rheumatic and musculoskeletal diseases.
- | Describe the opportunities that novel imaging provides in understanding the pathogenesis of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) and in the clinical management of PsA and axSpA.
- | Describe the benefits of early treatment of PsA and axSpA, and the recent expert consensus on the definition of early axSpA.
- | Highlight the unmet need in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) and the potential role of IL-17A inhibition in the clinical management of GCA and PMR.

Dr. SOFIA RAMIRO

Prof. Dr. GEORG SCHETT

Dr. HELENA MARZO-ORTEGA

Prof. Dr. WOLFGANG SCHMIDT

-
- 08:15 Welcome and introductions (S. Ramiro)
Evolving Picture: How IL-17A has transformed our understanding and treatment of rheumatic and musculoskeletal diseases (S. Ramiro)
 - 08:25 Looking Deeper: Novel imaging techniques in exploring the pathogenesis and treatment of SpA (G. Schett)
 - 08:40 Layered Insights: New evidence for defining and treating early PsA and axSpA (H. Marzo-Ortega)
 - 08:55 Advancing Further: Unmet needs and potential role of IL-17A inhibition in the management of GCA and PMR (W. Schmidt)
 - 09:15 Panel Discussion with Q&A (S. Ramiro, G. Schett, H. Marzo-Ortega, W. Schmidt)
 - 09:25 Meeting summary and close (S. Ramiro)

08:15–09:30 STRAUSS 2

SATELLITE SYMPOSIUM

ELI LILLY

DISPELLING COMMON MYTHS IN SPONDYLOARTHRITIS**LEARNING OBJECTIVE(S):**

- | To highlight how the latest ixekizumab evidence should evolve current practice in spondyloarthritis.
- | To exchange current opinion, knowledge and experiences to improve patient care in spondyloarthritis.
- | To increase confidence among the rheumatologist community for using ixekizumab in their daily practice.

Dr. JUDITH SAUTNER

Dr. VICTORIA NAVARRO-COMPAN

Dr. WILLIAM TILLET

Dr. FABIAN PROFT

-
- 08:15 The Whispered secrets of SpA: beyond TNFi (J. Sautner, V. Navarro, W. Tillett, F. Proft)
 - 08:33 IL-17i's dance of destiny: identical or fraternal? (J. Sautner, V. Navarro, W. Tillett, F. Proft)
 - 08:51 Treating PsO, the painted veil of skin, may lull the PsA serpent! (J. Sautner, V. Navarro, W. Tillett, F. Proft)
 - 09:09 The Silent Flame's Deception: When Normal Inflammation Conceals Unyielding Symptoms in axSpA (J. Sautner, V. Navarro, W. Tillett, F. Proft)

08:15–09:30 STOLZ 1

SATELLITE SYMPOSIUM

GSK**EGPA CARE REIMAGINED: BIOLOGICS THROUGH THE LENS OF RWE****LEARNING OBJECTIVE(S):**

- | Explore the roles of eosinophils and ANCA in EGPA and the importance of biomarker testing for timely diagnosis.
- | Emphasise the importance and need for timely intervention with mepolizumab for patients with EGPA.
- | Evaluate strategies for improving patient outcomes and discuss Clinical Remission as an achievable treatment goal for patients with EGPA.

Prof. Dr med. BERNHARD HELLMICH

Dr. ROBERTO PADOAN

Dr. ANISHA DUA

-
- 08:15 Welcome and introduction (B. Hellmich)
 - 08:25 Advancing EGPA care: The importance of biomarkers (B. Hellmich)
 - 08:45 Progressing patient outcomes: Timely intervention with biologic treatment (R. Padoan)
 - 09:00 Clinical Remission: Moving towards an achievable treatment goal (A. Dua)
 - 09:25 Summary and close (B. Hellmich, R. Padoan, A. Dua)

08:15–09:30 SESSION ROOM A8.2

SATELLITE SYMPOSIUM

BRISTOL MYERS SQUIBB**WHAT MAKES DEUCRAVACITINIB TYK?****LEARNING OBJECTIVE(S):**

- | Discuss signaling regulated by the Janus Kinase (JAK) family (JAK1/2/3 and Tyrosine kinase 2 (TYK2)) and explore which cytokine pathways are impacted by each member.
- | Describe the deucravacitinib mechanism of action.
- | Review how emerging data supports the potential of deucravacitinib in rheumatology.

Prof. Dr. JOSEF SMOLEN

Prof. Dr. HENDRIK SCHULZE-KOOPS

Prof. ALBERTO CAULI

Prof. JOAN MERRILL

-
- 08:15 Welcome and introduction (J. Smolen)
 - 08:20 JAK Family: Who, What, Why? (J. Smolen)
 - 08:45 What makes deucravacitinib different? (H. Schulze-Koops)
 - 08:55 Emerging clinical trial evidence (A. Cauli, J. Merrill)
 - 09:15 Audience Q&A (J. Smolen, H. Schulze-Koops, A. Cauli, J. Merrill)

WE ARE PLEASED TO SHARE THE DETAILS OF THIS EULAR
EUROPEAN CONGRESS OF RHEUMATOLOGY 2024
ALFASIGMA-SPONSORED INDUSTRY SYMPOSIUM

JAK inhibitors in practice: unlocking the potential in the real world of RA

Wednesday 12 June 2024 | 18:30–19:45 CEST
Session room A8.2, Messe Wien Exhibition
& Congress Center, Vienna, Austria

Faculty



Professor Maya Buch (Chair)
University of Manchester, UK



Professor Gerd R. Burmester
Charité – University Medicine
Berlin, Germany



Professor Cécile Gaujoux-Viala
Desbrest Institute of Epidemiology and
Public Health, University of Montpellier
and Nîmes University Hospital,
Nîmes, France



Professor Roberto Caporali
University of Milan, Italy

In this Alfasigma-sponsored industry symposium, our expert faculty will:

- Explore the importance of real-world evidence (RWE) and how it can be interpreted for use in clinical decision-making for patients with RA
- Discuss how RWE expands on efficacy and safety data from randomised controlled trials of JAK inhibitors in patients with RA
- Explore real-world case studies of patients with RA treated with filgotinib in FILOSOPHY

Join us for this stimulating symposium in which our experts will tackle these topics and answer your questions

We hope to see you there!

08:15–09:30 STRAUSS 3

SATELLITE SYMPOSIUM

BOEHRINGER INGELHEIM**SYSTEMIC SCLEROSIS: ADDRESSING THE CHALLENGES****LEARNING OBJECTIVE(S):**

- | Discuss the potential to improve outcomes for patients with systemic sclerosis (SSc) through early identification and treatment of complications.
- | Highlight the importance of using evidence-based guidelines while taking a patient-centric approach to management of SSc.

Prof. CHRISTOPHER P. DENTON

Prof. FRANCESCO DEL GALDO

Dr. ELIZABETH VOLKMANN

Dr. ANNA-MARIA HOFFMANN-VOLD

08:15	Introduction (C. Denton)
08:25	Optimising the window of opportunity for intervention (F. Del Galdo)
08:40	Predicting and monitoring the course of a heterogeneous disease (E. Volkmann)
08:55	Individualising treatment decisions (A.M. Hoffmann-Vold)
09:10	Q&A (C. Denton, F. Del Galdo, E. Volkmann, A.M. Hoffmann-Vold)

08:15–09:30 STOLZ 2

SATELLITE SYMPOSIUM

MERCK**TOLL-LIKE RECEPTORS: AN EVOLVING STORY IN LUPUS****LEARNING OBJECTIVE(S):**

- | Establish the need for new treatment options in lupus (SLE and CLE).
- | Emphasise new evidence on the burden of lupus.
- | Showcase the latest science on the pathophysiology of lupus.
- | Highlight the role of TLR/8 in innate immunology-driven pathways of lupus.
- | Raise awareness of challenges in clinical trials for lupus, and new approaches to address those challenges.
- | Raise awareness of Merck TLR/8 inhibition clinical development activities.

Prof. ERIC MORAND

Dr. CAROLA VINUESA

Prof. Dr. med. MIRIAM WITTMANN

-
- 08:15 Welcome and opening (E. Morand)
 - 08:25 Lupus pathophysiology and the role of Toll-Like Receptors (C. Vinuesa)
 - 08:40 Current approaches to CLE (M. Wittmann)
 - 08:55 TLR7/8 inhibition in SLE and CLE (E. Morand)
 - 09:15 Q&A (E. Morand, C. Vinuesa, M. Wittmann)

09:45–10:15 CONSULT THE EXPERT 2

CONSULT THE EXPERT

JOHNSON & JOHNSON**WITH A LITTLE HELP FROM MY PEERS: CHALLENGING PSA CASES IN DAILY PRACTICE****LEARNING OBJECTIVE(S):**

- | Differentiate therapies for PsA based on their mechanisms of action, efficacy/ effectiveness, and safety profiles.
- | Integrate patient and disease characteristics (including domains), the burden of psoriatic disease, comorbidities, concomitant diseases, and quality of life into PsA management.

Dr. RICHARD SMITH
 Dr. ANNA MOLTO
 Prof. Dr. PHILIPP SEWERIN

09:45	Welcome and introduction (R. Smith)
09:48	Safety is at the heart of it: IL-23 inhibitors and cardiovascular disease (A. Molto)
09:56	Busting myths: IL-23 inhibitors and cancer (P. Sewerin)
10:04	Q&A and panel discussion (A. Molto, P. Sewerin, R. Smith)
10:12	Closing remarks (R. Smith)

09:45–10:15 CONSULT THE EXPERT 1

CONSULT THE EXPERT

GSK**SEIZING THE WINDOW OF OPPORTUNITY IN LUPUS: HOW TO ACHIEVE DISEASE MODIFICATION****LEARNING OBJECTIVE(S):**

- | To educate on the need for disease modification – and the possibility of achieving it – for people living with SLE
- | To highlight the importance of preventing organ damage in SLE through early intervention, raising the idea of a “window of opportunity” for optimal disease management

Prof. MARIA DALL'ERA
 Prof. MARTA MOSCA

09:45	Seizing the Window of Opportunity in Lupus: How to Achieve Disease Modification (M. Dall'Era, M. Mosca)
-------	---

09:45–10:15 CONSULT THE EXPERT 3

CONSULT THE EXPERT

SOBI**MACROPHAGE ACTIVATION SYNDROME IN STILL'S DISEASE –
CURRENT STATE AND FUTURE HORIZONS OF PATIENT
MANAGEMENT****LEARNING OBJECTIVE(S):**

- | Participants will gain a comprehensive understanding of the current diagnostic and therapeutic approaches in the management of sHLH & MAS in Still's Disease, and explore the potential future advancements, novel therapies, and research directions that may shape the landscape.

Prof. FABRIZIO DE BENEDETTI

-
- 09:45 Aligning Our Practice with Progress: Patient Management in Harmony with Current Guidelines to Envisioning the Future Without Restrictions (F. De Benedetti)
09:55 Interactive Exploration of a Patient Case – Unravelling Complexity (F. De Benedetti)
10:05 Q&A and Closure (F. De Benedetti)

15:00–15:30 CONSULT THE EXPERT 3

CONSULT THE EXPERT

NOVARTIS**FMF: THE ROLE OF CANAKINUMAB IN THE TREATMENT PARADIGM****LEARNING OBJECTIVE(S):**

- | To share expert opinion on the disease activity measures and treatment recommendations in patients with FMF.
- | To raise awareness of the potential benefit of the early use of IL-1 inhibitors in patients with FMF.
- | To highlight the role of canakinumab in achieving sustained clinically inactive disease when used as a first-line biologic therapy.

Prof. SEZA OZEN

Prof. Dr. LUCA CANTARINI

-
- 15:00 Welcome and introductions (S. Ozen)
15:03 Achieving early and sustained clinically inactive disease in FMF: case study discussion (S. Ozen, L. Cantarini)
15:18 Q&A session and close (S. Ozen, L. Cantarini)

15:00–15:30 CONSULT THE EXPERT 1

CONSULT THE EXPERT

GSK

PRACTICAL CONSIDERATIONS WHEN ADVANCING LUPUS CARE**LEARNING OBJECTIVE(S):**

- | In this interactive discussion, experts will share real clinical experience with managing SLE, encourage proactive thinking about treating earlier to reduce the risk of organ damage progression, and consider the challenges of tapering steroids to zero.

Prof. Dr. ANDREA DORIA

Prof. FULVIA CECCARELLI

15:00 Curbside consultation (A. Doria, F. Ceccarelli)

17:30–18:45 SESSION ROOM C8

SATELLITE SYMPOSIUM

ABBVIE**ALL ABOARD!: CHOOSING THE RIGHT TRACKS TO ACCELERATE PATIENTS WITH RA AND SPA TOWARD THEIR GOALS****LEARNING OBJECTIVE(S):**

- | Discuss the importance of stringent disease control on the daily lives of patients and describe strategies to help patients with RA, PsA or axSpA reach their lowest possible disease activity as early as possible and maintain it over time.
- | Compare and contrast the different treatment options for stringent disease control, applying the latest trial data (long-term) and real-world JAK inhibitor evidence.
- | Identify common barriers, and potential solutions, in achieving stringent disease control.

Prof. MAYA BUCH

Dr. EDURADO MYSLER

Dr. ALEXIS OGDIE

-
- 17:30 Identifying the Destination (M. Buch)
 - 17:55 Selecting the Right Course (E. Mysler, A.Ogdie)
 - 18:25 The Patient Journey: Navigating Obstacles (M. Buch, E. Mysler, A.Ogdie)

17:30–18:45 SESSION ROOM C7

SATELLITE SYMPOSIUM

UCB

TIME TO REVOLUTIONISE CLINICAL PRACTICE? STRIVING FOR RESOLUTION OF INFLAMMATION WITH THE DUAL INHIBITION OF IL-17A AND IL-17F IN PSA AND AXSPA**LEARNING OBJECTIVE(S):**

- | To demonstrate that strict control of inflammation is linked to improved disease outcomes in PsA and axSpA
- | To explore the role of dual inhibition of IL-17A and IL-17F in achieving resolution of inflammation in PsA and axSpA

Prof. IAIN B. MCINNES

Prof. MARIA ANTONIETTA D'AGOSTINO

Prof. MARTIN RUDWALEIT

17:30	Welcome and introduction (I. McInnes)
17:35	Navigating Resolution of Inflammation in PsA and axSpA: The Role of IL-17A and IL-17F (I. McInnes)
17:53	Advancing Psoriatic Arthritis Care Through Control of Inflammation (M.A. D'Agostino)
18:11	Advancing Axial Spondyloarthritis Care Through Control of Inflammation (M. Rudwaleit)
18:29	"Cutting to the Chase" – Practical Considerations for the Clinic and Overall Conclusions (I. McInnes)
18:35	Panel Discussion and Q&A: Perspectives on the Future of PsA and axSpA Treatment Strategies (I. McInnes, M.A. D'Agostino, M. Rudwaleit)

17:30–18:45 STRAUSS 1

SATELLITE SYMPOSIUM

PFIZER**EXPERT PERSPECTIVES: CROSS-SPECIALITY APPLICATIONS OF TOFACITINIB IN AS AND UC****LEARNING OBJECTIVE(S):**

- | Share experiences, discuss practical advice, and identify comanagement strategies for patients in the context of a complex AS patient case with an EMM.
- | Apply learnings from AS and UC clinical studies to optimise treatment strategies.
- | Explore the breadth of safety data available across indications.

Dr. JANET POPE

Prof. Dr. FRANK BEHRENS

Prof. Dr. CHARLIE LEES

-
- 17:30 Welcome and introduction (J. Pope)
 - 17:35 Meet our AS patient with IBD (F. Behrens, C. Lees)
 - 17:40 Versatility in action: experiences across indications (F. Behrens, C. Lees)
 - 18:00 Safety considerations for tofacitinib across indications (F. Behrens, C. Lees, J. Pope)
 - 18:10 Audience Q&A (F. Behrens, C. Lees, J. Pope)
 - 18:40 Closing remarks (J. Pope)

17:30–18:45 SESSION ROOM A8.1

SATELLITE SYMPOSIUM

JOHNSON & JOHNSON**THE CYCLE OF INFLAMMATION: IL-23 ACROSS PSORIATIC DISEASE****LEARNING OBJECTIVE(S):**

- | Differentiate therapies for PsA based on their mechanisms of action, efficacy/ effectiveness, and safety profiles.
- | Integrate patient and disease characteristics (including domains), the burden of psoriatic disease, comorbidities, concomitant diseases, and quality of life into PsA management.
- | Evaluate the benefits of cross-specialty collaboration in the management of PsA and patient comorbidities and concomitant diseases.

Prof. Dr. GEORG SCHETT
Dr. ANDREAS KERSCHBAUMER
Dr. LAURA SAVAGE
Prof. Dr. ALEXANDER MOSCHEN
Prof. DENNIS MCGONAGLE

17:30	Welcome and introduction (G. Schett)
17:35	From head to toes: IL-23 in the MSK domains (A. Kerschbaumer)
17:45	Panel Discussion (G. Shett, A. Kerschbaumer, L. Savage, A. Moschen, D. McGonagle)
17:50	Below the surface: IL-23 in the gut (A. Moschen)
17:55	In plain sight: IL-23 in the skin (L. Savage)
18:05	Panel Discussion (G. Shett, A. Kerschbaumer, L. Savage, A. Moschen, D. McGonagle)
18:15	Is there an issue in the tissue? The joint perspective (D. McGonagle)
18:25	Is there an issue in the tissue? The gut perspective (A. Moschen)
18:30	Panel Discussion (G. Shett, A. Kerschbaumer, L. Savage, A. Moschen, D. McGonagle)
18:40	Closing Remarks (G. Schett)

17:30–18:45 SESSION ROOM A8.2

SATELLITE SYMPOSIUM

ASTRAZENECA**THE MISSION FOR REMISSION: WHAT IS NOW POSSIBLE FOR OUR PATIENTS?****LEARNING OBJECTIVE(S):**

- | Communicate the importance and attainability of early and sustained remission in SLE
- | Outline updates to SLE management guidelines and discuss how prompt action in targeting key drivers of disease and damage can provide rapid responses and improved long-term outcomes for patients.
- | Highlight a role for anifrolumab in achieving remission early in the disease course and discuss effective implementation of innovative therapeutic approaches in real-world clinical practice through exploration of patient cases.

Prof. Dr. ANDREA DORIA

Dr. MARIA GALINDO-IZQUIERDO

Dr. TOBIAS ALEXANDER

Dr. FRANCOIS CHASSET

-
- 17:30 Redefining SLE management: prioritising remission for our patients (A. Doria)
 - 17:45 Targeted treatment to achieve our goals: exploring the evidence (M. Galindo- Izquierdo)
 - 18:05 Implementing innovative approaches: expert perspectives from the clinic (T. Alexander, F. Chasset)
 - 18:35 Q&A and close (A. Doria, M. Galindo, T. Alexander, F. Chasset)

17:30–18:45 STRAUSS 2

SATELLITE SYMPOSIUM

BRISTOL MYERS SQUIBB**CAR T THERAPY – BRINGING A DECADE OF SUCCESSFUL EXPERIENCE TO PATIENTS WITH AUTOIMMUNE DISEASES****LEARNING OBJECTIVE(S):**

- | Highlighting the unmet needs of patients with severe refractory SLE, IIM and SSc (the patient's perspective).
- | Providing important learnings from the use of CAR T-cell therapy in patients with haematological diseases that can be transferred to the use of CAR T-cell in patients with autoimmune diseases such as the role of T-cell fitness for successful manufacturing, medications which can harm T-cell fitness, biomarkers that correlate with improved outcomes.
- | Considerations for developing CAR T-cell therapies for patients with autoimmune diseases, such as the role of referrals, the need for patient education, the importance of sharing the experience of the CAR T-cell journey and the joint care model involving rheumatologists and hematologists.

Prof. ANCA ASKANASE

Prof. Dr. RICARDO GRIESHABER-BOUYER

Dr. ASHLEY KOEGEL

Ms. SANDRA JELEAZCOV

17:30	Unmet Needs in Patients with Treatment-Resistant SLE, IIM and SSc (R. Grieshaber-Bouyer)
17:45	Why CAR T? the patient's view (S. Jeleazcov)
18:05	Optimizing CAR T Therapy: Challenges and Opportunities (A. Koegel)
18:20	CAR T as the NEX-T Best Thing for patients with SLE, IIM and SSc? (A. Askanase)
18:35	Q&A and conclusions (A. Askanase)

17:30–18:45 STRAUSS 3

SATELLITE SYMPOSIUM

BOEHRINGER INGELHEIM**TACKLING INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS OR RHEUMATOID ARTHRITIS****LEARNING OBJECTIVE(S):**

- | Discuss how recently published guidelines can inform the management of patients with systemic sclerosis-associated ILD (SSc-ILD) or rheumatoid arthritis-associated ILD (RA-ILD).
- | Highlight the importance of taking a patient-centric approach to the management of SSc-ILD and RA-ILD.

Dr. JEFFREY A SPARKS

Dr. ANNA-MARIA HOFFMANN-VOLD

Dr. PILAR RIVERA ORTEGA

-
- | | |
|-------|---|
| 17:30 | Introduction (J. A. Sparks) |
| 17:35 | Guidelines for treatment of autoimmune rheumatic disease-related ILDs: a step forward? (A.M. Hoffmann-Vold) |
| 17:50 | Challenges in clinical practice: patient case studies (J. A. Sparks, A.M. Hoffmann-Vold, P. R. Ortega) |
| 18:10 | Looking to the future: trials of new therapies for autoimmune rheumatic disease-related ILDs (J. A. Sparks) |
| 18:20 | Questions and answers (J. A. Sparks, A.M. Hoffmann-Vold, P. R. Ortega) |

17:30–18:45 STOLZ 1

SATELLITE SYMPOSIUM

CSL VIFOR**EXCELLENCE IN ANCA-ASSOCIATED VASCULITIS (AAV) – FROM DIAGNOSIS TO OPTIMAL CARE****LEARNING OBJECTIVE(S):**

- | To discuss the range and burden of disease manifestations in ANCA-associated vasculitis (AAV), including dermatological, pulmonary, ENT, and renal manifestations.
- | To discuss the importance of different manifestations for the differential diagnosis of vasculitides, vasculitis disease severity and prognosis.
- | To discuss management decision making in patients with different comorbidities; To discuss the rationale for a MDT approach to the management of AAV, and the benefits this brings.

Prof. Dr. JENS THIEL

Prof. Dr. med. CORD SUNDERKÖTTER

Prof. Dr. med. GUNTER ASSMANN

Assist. Prof. ANDREAS KRONBICHLER

-
- 17:30 Vasculitis Excellence in practice – a local perspective n (J. Thiel)
 - 17:40 Getting under the skin – AAV and dermatology (C. Sunderkötter)
 - 17:55 Different organ manifestations and therapeutic situations in ANCA-associated vasculitis (G. Assmann)
 - 18:15 Balancing renal considerations in AAV – from diagnosis to treatment (A. Kronbichler)
 - 18:30 Questions & Answers (J. Thiel, C. Sunderkötter, G. Assmann, A. Kronbichler)
 - 18:43 Concluding remarks (J. Thiel)

For healthcare professionals only

EULAR European Congress of Rheumatology 2024 Industry Symposia

AstraZeneca-organised and -funded satellite symposium



The mission for remission: what is now possible for our patients?

Thursday 13 June 2024 | 17:30-18:45 CEST | Room A8.2

Redefining SLE management: prioritising remission for our patients

Andrea Doria

Targeted treatment to achieve our goals: exploring the evidence

Maria Galindo

Implementing innovative approaches: expert perspectives from the clinic

François Chasset and Tobias Alexander

Q&A and close

All faculty

This promotional symposium is organised and funded by AstraZeneca. AstraZeneca products will be discussed.

Prescribing information is available at the meeting and may also be found at the AstraZeneca booth.

Veeva ID: AT-11470; Date of preparation: April 2024



Andrea
Doria
(Chair)



Maria
Galindo



François
Chasset



Tobias
Alexander

AstraZeneca

 **clarius** Ultrasound
Anywhere

High-Resolution
Wireless
Ultrasound For
Endocrinology



**High-Resolution
Ultrasound**

Best in-class imaging
for handheld ultrasound



**Easy-to-Use App
for iOS and Android**


Improve workflows with
specialized tools



**Wireless and
Portable**

Perform quick exams
from patient to patient

Real-Time Anatomical Overlays*



* T-Mode AI is for educational and training purposes only

LEARN MORE

www.clarius.com

INDUSTRY
PROGRAMME
ON
FRIDAY
14 JUNE 2024

Status as of 13 May 2024

08:15–09:30 STOLZ 2

SATELLITE SYMPOSIUM

GSK**EGPA: EXPLORING THE EMERGING EVIDENCE****LEARNING OBJECTIVE(S):**

- | Facilitate a deeper scientific understanding of the immunological and pathophysiological drivers of disease in EGPA.
- | Explore the impact of therapies on both underlying immunology and translation to clinical outcomes for patients.

Prof. MICHAEL WECHSLER

Prof. SALMAN SIDDIQUI

Prof. Dr. JENS THIEL

08:15	Welcome and introductions (M. Wechsler)
08:20	Understanding the burden of EGPA (J. Thiel)
08:40	Untangling the immunological basis of EGPA (S. Siddiqui)
09:00	Optimising EGPA treatment: Translating data into clinical practice (M. Wechsler)
09:20	Q&A and take-home messages (M. Wechsler, J. Thiel, S. Siddiqui)

08:15–09:30 STRAUSS 2

SATELLITE SYMPOSIUM

MEDAC**OPTIMISING METHOTREXATE – HOW TO ACHIEVE MAXIMUM RESULTS WITH THE ANCHOR DRUG OF RA THERAPY****LEARNING OBJECTIVE(S):**

- | Learn more on the management of patients with rheumatoid arthritis (RA) by using first-line medication methotrexate (MTX) optimally, for example, when initiating RA therapy. Although used for decades, data on the use of application routes and dosage escalation in the early phase of first-line therapy was lacking. Now, a retrospective study from France will be presented that compared oral vs. subcutaneous MTX in early RA. Also, data will be reviewed regarding the therapy of patients with juvenile idiopathic arthritis (JIA). Finally, the outcome of close dermatological-rheumatological collaborations will be discussed with the goal to earlier diagnose and initiate systemic treatment for psoriatic arthritis (PsA) with methotrexate being the most prescribed medication for this patient group.

Prof. Dr. ULF MÜLLER-LADNER

Prof. JEROME AVOUAC

Prof. PAVLA DOLEZALOVA

Prof. Dr. VALENTIN SCHÄFER

08:15	Welcome (U. Müller-Ladner)
08:20	Clinical benefits of the subcutaneous methotrexate in RA therapy (U. Müller-Ladner)
08:35	Comparison of subcutaneous versus oral MTX for initiating RA therapy (J. Avouac)
08:50	Improving therapy with conventional DMARDs in juvenile idiopathic arthritis (P. Dolezalova)
09:05	Rheumatological-dermatological cooperation: Earlier psoriatic arthritis diagnosis and improved therapy with conventional medications (V. Schäfer)
09:20	Discussion and Farewell (U. Müller-Ladner)

08:15–09:30 STOLZ 1

SATELLITE SYMPOSIUM

OTSUKA**WHAT'S NEW IN LUPUS NEPHRITIS: FROM GUIDELINES TO REAL-WORLD PRACTICES****LEARNING OBJECTIVE(S):**

- | To provide the latest scientific data around Lupus Nephritis (LN) including biomarkers research.
- | To present key recent clinical trials in LN and updated EULAR and KDIGO guidelines.
- | To share real-world experiences with voclosporin treating LN patients in Europe.

Prof. Dr. CLEMENS SCHEINECKER

Dr. med. JOSEFINA CORTÉS-HERNANDEZ

Dr. RAVINDRA RAJAKARIAR

-
- | | |
|-------|--|
| 08:15 | Introduction (C. Scheinecker) |
| 08:20 | Hot topics in Lupus Nephritis: Vigilant monitoring – Urgency for screening (C. Scheinecker) |
| 08:35 | Key recent clinical trials and guidelines in Lupus Nephritis (J. Cortés-Hernandez) |
| 08:50 | 2 years of experience in Lupus Nephritis with the latest therapies in a real-world setting (R. Rajakariar) |
| 09:05 | Clinical cases of Lupus Nephritis patients (C. Scheinecker, J. Cortés-Hernandez, R. Rajakariar) |
| 09:20 | Q&A (C. Scheinecker, J. C. Hernandez, R. Rajakariar) |

08:15–09:30 SESSION ROOM A8.1

SATELLITE SYMPOSIUM

CABALETTA BIO

IMMUNE RESET: THE POTENTIAL OF CAR T CELL THERAPY TO TRANSFORM THE TREATMENT OF PATIENTS WITH AUTOIMMUNE DISEASE**LEARNING OBJECTIVE(S):**

- | Gain insight into the rationale and considerations for delivering a targeted B cell reset in patients with autoimmune disease.
- | Appraise the potential of CD19-CAR T cell therapy to reset the immune system through transient and deep B cell depletion.
- | Learn about an investigational fully human 4-1BB costimulatory domain-containing CD19-CAR T cell therapy in patients with lupus and myositis.

Dr. DAVID CHANG

Prof. Dr. GEORG SCHETT

Dr. CARL JUNE

-
- | | |
|-------|---|
| 08:15 | Welcome and Introduction (D. Chang) |
| 08:20 | Evolving the Potential of CAR T Cell Therapies to Autoimmunity (C. June) |
| 08:40 | Resetting the Immune System of Patients with Autoimmune Disease (G. Schett) |
| 09:00 | Unlocking the Potential of CD19-CAR T Cell Therapy in Lupus & Myositis (D. Chang) |

08:15–09:30 STRAUSS 3

SATELLITE SYMPOSIUM

KYVERNA**ANTI-CD19 CAR T-CELL THERAPY IN RHEUMATOLOGIC AUTOIMMUNE DISEASES AND BEYOND****LEARNING OBJECTIVE(S):**

- | Participants will learn about the latest data for the use of anti-CD19 CAR T-cell therapies in rheumatologic autoimmune diseases and a center's best practices for advancing clinical trials in this space.
- | The audience will gain an understanding of the potential of investigational CAR T-cell therapies, including KYV-101, an investigational anti-CD19 CAR T-cell therapy, in rheumatology and beyond. A multidisciplinary expert panel discussion will further comment on the advances in CAR T-cell therapies, addressing questions from the audience.

Prof. PETER A. MERKEL

Dr. PETER MAAG

Prof. GERHARD KRÖNKE

Dr. JAMES CHUNG

Dr. ROBERTO CARICCHIO

Dr. RICHARD A. FURIE

08:15	Welcome and Introduction (P. Maag)
08:20	Long-Term Clinical Experience and Mechanistic Insights (G. Krönke)
08:35	Advancing CAR T Trials in Rheumatologic Diseases (P. Merkel)
08:50	KYV-101 Experience Across Multiple Diseases and Sites? (J. Chung)
09:05	Panel Discussion (P. Merkel, G. Krönke, J. Chung, R. Caricchio, R. Furie)

09:45–10:15 CONSULT THE EXPERT 2

CONSULT THE EXPERT

UCB**UNLOCK YOUR YOUR DIGITAL IMPACT: SOCIAL MEDIA MASTER CLASS****LEARNING OBJECTIVE(S):**

- | Master dynamic strategies to elevate your digital footprint, forge connections with a diverse community of peers, build greater engagement, and foster open discussion from a broad range of perspectives.
- | Dive into patient perspectives on social media, understanding their journey to access accurate and relevant healthcare information, along with their expectations regarding content shared by healthcare professionals.
- | Explore how integrating medical education into social media platforms can foster stronger patient-provider relationships and positively impact treatment outcomes.

Dr. ROHIT AGGARWAL
Dr. SAAKSHI KHATTRI
Dr. AI LYN TAN

09:45 Elevating Digital Reach (R. Aggarwal, S. Khattri, A. L. Tan)

09:55 Navigating Patient (R. Aggarwal, S. Khattri, A. L. Tan)

10:05 Empowering Patient Provider Dynamics (R. Aggarwal, S. Khattri, A. L. Tan)

09:45–10:15 CONSULT THE EXPERT 3

CONSULT THE EXPERT

ASTRAZENECA

ACHIEVING DISEASE CONTROL ACROSS ORGAN SYSTEMS – EXPERT PERSPECTIVES FROM THE REAL WORLD

LEARNING OBJECTIVE(S):

- | Describe the commonalities in the mechanisms, drivers of disease activity and damage across the main organ manifestations of SLE.
- | Recognise the importance of a shared understanding of the disease, alignment on treatment goals across specialisms, and build confidence in achieving EULAR-recommended treatment targets, including remission as the primary goal of SLE treatment.
- | Explain how targeting a key driver of disease and damage, IFN-1, with anifrolumab can support early and sustained disease control across organ systems.

Prof. MARTA MOSCA

Dr. MARIA GALINDO-IZQUIERDO

-
- | | |
|-------|---|
| 09:45 | Targeted treatment and treatment targets: achieving disease control across manifestations of SLE (M. Mosca) |
| 09:55 | IFN blockade in practice: expert perspectives from the clinic (M. Galindo-Izquierdo) |
| 10:05 | Delegate Q&A, discussion and close (M. Mosca, M. Galindo-Izquierdo) |

09:45–10:15 CONSULT THE EXPERT 1

CONSULT THE EXPERT

GSK

THE POWER OF PREVENTION: WHY HERPES ZOSTER VACCINATION MATTERS IN PATIENTS WITH RHEUMATIC DISEASES**LEARNING OBJECTIVE(S):**

- | Drive urgency to help protect patients with rheumatic disease against shingles, by increasing awareness of the burden of herpes zoster (HZ) in this patient population.
- | Enhance HCPs understanding of the features, benefits and safety profile of the recombinant zoster vaccine, including: the latest data relevant to the 18+ year old increased-risk indication, guideline recommendations, and supportive data.
- | Provide practical guidance, and a forum for dynamic discussion, to raise awareness of the optimal integration of the recombinant zoster vaccine into the treatment of patients with rheumatic disease.

Prof. LEONARD CALABRESE

Prof. XAVIER MARIETTE

09:45 The risk and impact of herpes zoster in patients with rheumatic diseases: What do we know? (L. Calabrese)

09:50 Hands-on herpes zoster vaccination: Practical tips (L. Calabrese, X. Mariette)

17:30–18:45 STRAUSS 2

SATELLITE SYMPOSIUM

ASTRAZENECA**RHEUMATOLOGY MEETS PULMONOLOGY: HOLISTIC PERSPECTIVES FOR EGPA****LEARNING OBJECTIVE(S):**

- | Using an interactive case study, this symposium aims to explore the patient journey for eosinophilic granulomatosis with polyangiitis (EGPA) from the perspective of different specialties, highlighting challenges and novel multidisciplinary approaches to disease management. The symposium will include focused discussions on the role of eosinophils in EGPA pathophysiology and the current unmet needs for patients.

Prof. BERNHARD HELLMICH

Prof. SALMAN SIDDIQUI

Dr. SARA MONTI

-
- 17:30 Welcome and Introduction (B. Hellmich)
 - 17:40 A challenging disease presents challenging cases (S. Siddiqui)
 - 18:00 Investigating the cause of the problem (S. Monti)
 - 18:15 Optimising the management of EGPA (B. Hellmich)
 - 18:30 Audience Q&A (B. Hellmich, S. Monti, S. Siddiqui)
 - 18:40 Closing remarks (B. Hellmich)

17:30–18:45 STOLZ 1

SATELLITE SYMPOSIUM

AMGEN**WHAT'S NEW IN IGG4-RELATED DISEASE AND WHERE DO WE GO NEXT****LEARNING OBJECTIVE(S):**

- | Discuss the obstacles to accurate and timely diagnosis of IgG4-RD.
- | Examine the B-cell mediated mechanism of disease in IgG4-RD.
- | Review the burden of disease and risk of recurrence for patients with IgG4-RD.
- | Introduce considerations for long-term maintenance treatment to prevent IgG4-RD flares.

Prof. JOHN H. STONE

Ast. Prof. EMANUEL DELLA TORRE

Dr. FERNANDO MARTINEZ VALLE

Dr. TOBIAS ALEXANDER

17:30	Welcome and Introductions (J. Stone)
17:35	The Great Impersonator – Diagnosis of IgG4-RD (J. Stone)
17:50	The Inner Workings – Pathophysiology of IgG4-RD (E. D. Torre)
18:05	Burden of Disease – Risk of Recurrence, End Organ Damage, and New Organ Involvement (F. M. Valle)
18:15	Identity Revealed – Current Management Approaches and Controversies in Long-term Management (T. Alexander)
18:30	Questions & Answers (J. Stone, E. D. Torre, F. M. Valle, T. Alexander)
18:40	Concluding Remarks (J. Stone)

17:30–18:45 STOLZ 2

SATELLITE SYMPOSIUM

SANOFI**UNVEILING THE CLINICAL CANVAS: NAVIGATING UNMET NEEDS IN POLYMYALGIA RHEUMATICA****LEARNING OBJECTIVE(S):**

- | The clinical picture of polymyalgia rheumatica (PMR), epidemiology, treatment landscape, treatment guidelines, and unmet medical needs such as limited steroid efficacy, steroid burden, including toxicity (even with low dose), and frailty.
- | The different immune pathways involved in the pathophysiology of PMR, the role of synovocytes in inflammation (bursitis, tendonitis), the overlap with other inflammatory rheumatic diseases such as rheumatoid arthritis and giant cell arteritis, and the role of the immune system in the systemic manifestations of PMR, including fatigue and pain.
- | The latest studies and results by class of therapy including open label extension studies, randomized-controlled trials, and real-world evidence studies.

Prof. BHASKAR DASGUPTA

Prof. ERNEST CHOY

Prof. Dr. Med. FRANK BUTTGEREIT

Dr. ALVIN WELLS

17:30	Welcome and Introductions (B. Dasgupta)
17:35	The Silent Crisis of Polymyalgia Rheumatica (A. Wells)
17:50	Decoding the Immunopathophysiology of Polymyalgia Rheumatica: Unraveling the Mysteries Within (E. Choy)
18:05	Road from Immunopathophysiology to Therapy of Polymyalgia Rheumatica (F. Buttgereit)
18:20	Poll / Q&A (B. Dasgupta)
18:40	Closing Remarks (B. Dasgupta, E. Choy, F. Buttgereit, A. Wells)

EULAR INDUSTRY PARTNERS

Status as of 21 May 2024

CORPORATE MEMBERS

ABBVIE	56
UCB	57
PFIZER	58
JOHNSON & JOHNSON	59
NOVARTIS	59
ELI LILLY	60
ASTRAZENECA	61
GSK	62
BRISTOL MYERS SQUIBB	62
ALFASIGMA	63
MEDAC	64
BOEHRINGER INGELHEIM	65
AMGEN	66
ROCHE	67
CSL VIFOR	68
IBSA INSTITUT BIOCHIMIQUE	68
FRESENIUS KABI	69
CELLTRION HEALTHCARE	70
OTSUKA	70
BIOGEN	71
MERCK	71
SOBI	72

CORPORATE NON-MEMBERS

ACCORD HEALTHCARE	73
ACELYRIN	73
ADAMO SRL	74

ALPINE IMMUNE SCIENCES	75
ALPINION	76
ARGENX	76
BMJ	77
CABALETTA BIO	78
CESAS MEDICAL	78
CLARIUS MOBILE HEALTH	79
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	80
ESAOTE	80
LABORATOIRES EXPANSCIENCE	81
GE HEALTHCARE	81
KYVERNA	82
LA LETTRE DU RHUMATOLOGUE	82
MSD	83
NORDIC PHARMA	83
REIG JOFRE	84
SANA BIOTECHNOLOGY	85
SANOFI	86
TAKEDA	87
THE JOURNAL OF RHEUMATOLOGY	87
THERMO FISHER SCIENTIFIC	88
VIATRIS	88
WISEPRESS	89
XIRALITE	89
ZENAS BIOPHARMA	90

YOU CAN FIND OUR INDUSTRY PARTNERS AT ...

THE EXHIBITION AREA HALL B, LEVEL 0

ABBVIE	C1+C2
ACCORD HEALTHCARE	D14
ACELYRIN	S4
ADAMO SRL	S16
ALFASIGMA	D1
ALPINION	S13.2
AMGEN	D2
ARGENX	S6
ASTRAZENECA	C4+C5
BIOGEN	S24
BMJ	S5
BOEHRINGER INGELHEIM	D4+D5+D7
BRISTOL-MYERS SQUIBB	D6
CABALETTA BIO	S18+S19
CELLTRION HEALTHCARE	A10
CESAS MEDICAL	S17
CLARIUS MOBILE HEALTH	S10
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	S15
CSL VIFOR	A8
ELI LILLY	C3
ESAOTE	S13
EXPANSCIENCE LABORATORIES	D11
FRESENIUS KABI	B4

GE HEALTHCARE	D8
GSK	A5+A6+A7
IBSA INSTITUTE BIOCHIMIQUE	A9
JOHNSON & JOHNSON	D3
KYVERNA	S22+S23
LA LETTRE DU RHUMATOLOGUE	S8+S9
MEDAC	A1
MERCK	S1+S2
NORDIC PHARMA	D13
NOVARTIS	B3
OTSUKA	B5
PFIZER	A2+A3
REIG JOFFRE	D9
ROCHE	A4
TAKEDA	S12
THE JOURNAL OF RHEUMATOLOGY	S3
THERMO FISHER SCIENTIFIC	S21
UCB	B1+B2
VIATRIS	S14
WISEPRESS	Bookshelf
XIRALITE	S11
ZENAS BIOPHARMA	S20

THE CORPORATE SCIENTIFIC WALKWAYS HALL B, LEVEL 0

ABBVIE	W2
ALFASIGMA	W3
ELI LILLY	W7

NOVARTIS	W6
UCB	W1

THE HOSPITALITY SUITES HALL A

ABBVIE	X1+X4
ACELYRIN	Y5.2
ALFASIGMA	Y3+Y4
ALPINE IMMUNE SCIENCES	X2
AMGEN	Y1+Y7+Z0
BRISTOL-MYERS SQUIBB	X6
ELI LILLY	Y6
FRESENIUS KABI	Z5
GSK	Z7+Z8
MSD	Y0

NOVARTIS	Z9+Z10
PFIZER	X5
ROCHE	Z6
SANA BIOTECHNOLOGY	Y2
SANOFI	Z1
SOBI	Y5.1
TAKEDA	Z3+Z4
UCB	X3
ZENAS BIOPHARMA	Z2

THE HOSPITALITY MEETING ROOMS HALL B, LEVEL 1

ASTRAZENECA	MR 5+6+7+8
BOEHRINGER INGELHEIM	MR 11+12
CSL VIFOR	MR 13+14
GSK	MR 15+16

JOHNSON & JOHNSON	MR 9+10+19+20
MERCK	MR 3+4
NOVARTIS	MR 1+2
SANOFI	MR 17+18

INDUSTRY PARTNERS

ABBVIE

AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people’s lives. Our commitment is measured by the impact we make – to patients, to our communities, and to the world. Our 50,000+ employees strive to make a remarkable impact that lasts, driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity. Today our products help more than 50 million people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow.



AbbVie
1 North Waukegan Road,
North Chicago, IL 60064
United States
www.abbvie.com



UCB

UCB is a global biopharmaceutical company focused on creating valuable solutions that make improvements to the lives of people living with neurological and autoimmune conditions now and into the future. At UCB, we believe that everyone deserves to live the best life that they can. UCB works closely and forges strong connections with patients, caregivers, healthcare professionals and other stakeholders who know the challenges and unmet needs of these diseases

At EULAR 2024, UCB strengthens its partnership with the rheumatology community by proudly sponsoring 2 scientific symposia and publishing new clinical data in several disease areas. Visit our Booth B1+B2 (Hall B) and Hospitality Suite X3 (Hall A) to find out more about our rheumatology portfolio and our ongoing partnerships.

© UCB Biopharma SRL, 2024. All rights reserved.
EU-DA-2400045 Date of preparation: February 2023
Intended for healthcare professionals



UCB
Allée de la Recherche, 60
1070 Brussels
Belgium
www.ucb.com

PFIZER

BREAKTHROUGHS THAT CHANGE PATIENTS' LIVES
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).



Pfizer
66 Hudson Boulevard East,
New York, NY 10001-2192
United States
www.Pfizer.com

JANSSEN PHARMACEUTICA NV

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Johnson&Johnson

Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse,
Belgium
www.janssen.com/emea

NOVARTIS

At Novartis we are reimaging medicine. As a leading global medicines company, we use innovative science and digital technologies to deliver high-value medicines for challenging and often-ignored conditions. We are continuing to bring unimagined possibilities to life through our relentless determination. With human compassion, commitment, and unwavering scientific curiosity, we develop and drive access to medicines for those who need them most. We are now building on our deep therapy area expertise in rheumatology, prioritizing often-ignored conditions such as Sjögren's disease, systemic lupus erythematosus and lupus nephritis, to better serve those with few, or inadequate, options.



Novartis Pharma AG
Basel
CH-4002
Switzerland
www.novartis.com

ELI LILLY AND COMPANY

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit our website.

Our promise to people living with rheumatic diseases
Creating Brighter Futures

By following the science – sometimes into uncharted territory – we continue Lilly’s legacy of delivering innovative medicines that address unmet needs and have a profound and significant impact on people’s lives around the world.

Rheumatic diseases are uncompromisingly complex. They can have a devastating impact on people’s lives. That’s why we are determined to create brighter futures for people with debilitating rheumatic diseases through innovative discoveries and patient-centered solutions.



Eli Lilly and Company
Indianapolis, IN 46285
USA
www.lilly.com

ASTRAZENECA

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca



AstraZeneca
1 Francis Crick Avenue
Cambridge Biomedical Campus,
Cambridge,
CB2 0AA
United Kingdom
www.astrazeneca.com

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We are working to unlock the science of the immune system to improve outcomes for people affected by immune-mediated conditions. We will be sharing and discussing the latest science and emerging evidence around immune-mediated conditions at EULAR 2024. Please visit us at our booth, attend our industry symposia and consult the expert educational sessions, to learn more about GSK in immunology.

Intended for HCPs only.

@2024 GSK group of companies. All rights reserved.

Date of preparation: February 2024

NP-GBL-IM-WCNT-240001



GSK

980 Great West Road Brentford,

Middlesex TW8 9G

United Kingdom

www.gsk.com

BRISTOL MYERS SQUIBB

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.



Bristol Myers Squibb

3401 Princeton Pike

Lawrence Township, NJ

USA 08648

www.bms.com

ALFASIGMA

Alfasigma is one of the leading Italian pharmaceutical companies, operating in over 100 countries worldwide with approximately 4,000 employees dedicated to research, development, production, and distribution.

With more than 70 years of history, the Company has a longstanding track record in developing innovative therapeutic indications to meet the new needs of patients while renewing and consolidating its existing products. Its mission is to improve people's health and quality of life by offering caregivers and healthcare personnel therapeutic solutions according to the highest standards of quality and safety.

Alfasigma has a strong focus in the gastro-intestinal therapeutic area and worldwide has products also in vascular, metabolic areas and in nutraceuticals and medical foods. As part of its strategy to expand its specialty care portfolio in gastroenterology and rheumatology, Alfasigma strengthened its international presence with targeted acquisitions in US and Europe in 2023.

Alfasigma's historical headquarters are located in Bologna, with another office in Milan. It has production sites in Italy, in Pomezia (RM), Alanno (PE), Sermoneta (LT) and Trezzano Rosa (MI), and abroad in Tortosa, Spain and in Shreveport (Louisiana) in the United States. Its R&D Lab Centers are in Pomezia (RM) and in the Kilometro Rosso Innovation District in Bergamo.

For more information, visit the Company website at www.alfasigma.com or connect with the Company on LinkedIn



Alfasigma S.p.A.
Via Ragazzi del '99, 5
Bologna
Italy
www.alfasigma.com

MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH

At medac group, we believe that health is humanity's most valuable resource. Since 1970, our mission has been to improve patients' quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in 91 countries. With more than 2.000 employees we are committed to improving human health.

All our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.

We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, hematology, and oncology. Part of our mission is to provide safe, high-quality and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.



medac GmbH
Theaterstraße 6
22880 Wedel
Germany
www.medac.de

BOEHRINGER INGELHEIM

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com

BOEHRINGER INGELHEIM IN INFLAMMATION

Living with inflammatory and fibrotic diseases greatly impacts patients' lives, both physically and emotionally. We remain strong in our 100-year commitment to leading scientific innovation across a range of respiratory conditions. We target scientific breakthroughs that seek to restore lung health in Pulmonary Fibrosis by understanding the disease heterogeneity, molecular pathways, biomarkers, and the mechanisms of fibrosis. We aim to stop disease progression/stabilize lung function decline and one day prevent Pulmonary Fibrosis.



Boehringer Ingelheim
International GmbH
Binger Straße 173
55216 Ingelheim
Germany
www.boehringer-ingelheim.com

AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.



Amgen (Europe) GmbH
Suurstoffi 22
6343 Rotkreuz
Switzerland
www.amgen.com

ROCHE

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

For more information, please visit our website.



F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
4070 Basel
Switzerland
www.roche.com

CSL VIFOR

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor, visit csl.com



CSL Vifor
Rechenstrasse 37
9014 St. Gallen
Switzerland
www.csl.com

IBSA

IBSA is an international pharmaceutical company headquartered in Lugano, Switzerland. Active in 10 therapeutic areas (OA, Pain, Dermatology, Cardiometabolic, Dermoaesthetic, Endocrinology, Human Reproduction, Respiratory, Urology, Consumer Health). The company has developed a series of proprietary technologies and patents allowing a qualitative upgrading of widely used molecules and therapeutic solutions. In the osteoarticular field, IBSA offers several therapeutic products, Condrosulf®, Sinovial® line and Sinogel®. Moreover, IBSA's pain and inflammation portfolio includes a range of various types of products for topical, oral and transdermal use under the Flector® brand.



Caring Innovation

IBSA Institut Biochimique SA
Via Pian Scaiolo 49
6912 Lugano-Pazzallo
Switzerland
www.ibsagroup.com

FRESENIUS KABI

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used for the therapy and care of critically and chronically ill patients.

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company's clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.

With its corporate mission of "caring for life", Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.

Following its "Vision 2026", the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.

For more information, please visit our website.



Fresenius Kabi
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
www.fresenius-kabi.com

CELLTRION HEALTHCARE CO., LTD.

Celltrion is a leading global biopharmaceutical company that researches, develops and manufactures antibody biosimilars, new biologics and small molecule drugs. Since our foundation, we have provided advanced and affordable treatment options for patients. We have presented a new paradigm to the global biologics market with the launch of the world's first antibody biosimilar. With our continuous effort to expand our biologics and small molecule drug portfolio, we help patients to return to their everyday lives in full wellness. Celltrion, as a global biopharmaceutical company with outstanding R&D know-hows, will continue to pursue its goal in promoting health and well-being of patients.



Celltrion Healthcare Co., Ltd
19, Academy-ro 51beon-gil
Yeonsu-gu,
Incheon, 22014
Korea

www.celltrionhealthcare.com

OTSUKA PHARMACEUTICAL

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.'

Our 47,000 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology, haemato-oncology and rare diseases.



Otsuka Pharmaceutical Italy S.r.l.
Via Fabio Filzi 29
20124 Milan
Italy

www.otsuka-europe.com

BIOGEN

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website. Follow us on social media - Facebook, LinkedIn, X, YouTube.



Biogen
Biogen Building 1
225 Binney Street Cambridge,
MA 02142
United States of America
www.biogen.com

MERCK KGAA

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).



MERCK KGAA
Headquarters of the Merck Group
Frankfurter Strasse 250
Darmstadt, 64293, Germany
Phone: +496151720
Fax: +496151722000
service@merckgroup.com
www.merckgroup.com

SWEDISH ORPHAN BIOVITRUM AB

Within the therapeutic area of Immunology, Sobi is dedicated to the treatment of rare, ultra-rare and severe diseases. This dedication combined with a rare expertise has resulted in a long history of developing transformative treatments for patients with high unmet medical needs. Our ability to identify unmet medical needs, develop treatments and secure evidence has been instrumental in the success of our current therapies. Our track record in getting innovative treatments to the people who need them positions us well to take a leading role in Immunology. We keep challenging the status quo and are dedicated to the continuous discovery of high-potential therapies that we can develop to make a lasting impact and create sustainable value, sooner rather than later. Through close collaboration with rare disease communities, we continue to improve access to care for those otherwise overlooked.



Swedish Orphan Biovitrum AB
SE-112 76 Stockholm, Sweden
Phone: +46(0)8 697 20 00
info@sobi.com
www.sobi.com

ACCORD HEALTHCARE

Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes generic, biosimilar and added-value medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care at the point of need. By challenging the status quo and directly addressing unmet clinical and societal needs, Accord continuously strives to make things better by delivering high quality medicines to patients, faster, more economically, reliably and with greater innovation than many other generic companies.

Accord's portfolio spans across critical therapeutic fields such as oncology, cardiology, neurology, psychiatry, diabetes, pain management and gastroenterology.

accord
We make it better

Accord Healthcare EMENA HQ
Sage House, 319 Pinner Road
North Harrow, Middlesex
HA1 4HF - London
United Kingdom
T: +44 (0) 208 863 1427
F: +44 (0) 208 863 1427
www.accord-healthcare.com

ACELYRIN

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN has two programs in late-stage clinical development. Izokibep is a next generation inhibitor of IL-17A in Phase 3 development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. For more information about ACELYRIN, visit us at www.acyelin.com.

Thank you for your interest in ACELYRIN, please reach out to info@acyelin.com for any inquiries.

ACELYRIN 

Acelyrin
4149 Liberty Canyon Rd
Agoura Hills, CA 91301
United States of America
www.acyelin.com

ADAMO S.R.L

Adamo S.r.l. comes from a multi-year experience in the field of video diagnostics in various specialized branches (rheumatology, dermatology, trichoscopy, etc.).

During the years we have introduced new diagnostic methods for better visualization of static and dynamic morphological patterns and we foresee to continue to develop new technology, allowing a more accurate clinical diagnosis, also thanks to our constantly investment in research and development.

Another highlight is that our systems are the result of constant collaboration with all of our Customers: the continuous feedback with them is our starting point to make more performing hardware and software.

We take care of every details!!!



Adamo S.r.l.
Via Francesco Culcasi n.1/B Z.I.R.
Trapani (TP)
Italy
Tel.+39 0923 558778
info@adamosrl.com
www.adamosrl.com

ALPINE IMMUNE SCIENCES



Alpine Immune Sciences is leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives.

Our lead development program is povetacept, a dual antagonist of the BAFF and APRIL cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacept has exhibited greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and B cell depletion. Povetacept is in development for multiple autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy and other autoimmune kidney diseases and autoimmune cytopenias.

Alpine Immune Sciences
188 East Blaine Street
Suite 200
Seattle, WA 98102
United States of America
www.alpineimmunesciences.com

ALPINION

“WE ARE ULTRASOUND PROFESSIONALS”

ALPINION MEDICAL SYSTEMS, founded in 2007, is a South Korean company specializing in advanced ultrasound imaging technology and solutions. Known for its innovation in medical diagnostics, ALPINION focuses on the development of ultrasound systems and transducer technology. ALPINION's ultrasound systems offer a broad range of single crystal transducers, beneficial for rheumatology and musculoskeletal diagnostics.

Our flagship X-CUBE series provides exceptional image quality, user-friendly interfaces, and advanced diagnostic capabilities, making it ideal for detailed musculoskeletal assessments and joint imaging crucial in rheumatology. From hand-held to high-end systems, ALPINION delivers a full-coverage portfolio. Headquartered in Seoul, ALPINION aims to contribute to the medical community by providing reliable, high-performance imaging solutions that support accurate diagnosis and efficient patient management.



ALPINION
2-4F, 15, Magokjungang 14-ro,
Gangseo-gu, Seoul, KOREA 07789
Tel: +82-2-3777-8600
www.alpinion.com

ARGENX

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.



Argenx
Industriepark Zwijnaarde 7
9052 Zwijnaarde (Ghent)
Belgium
Tel: +43 (0)676 9335422
sschmidt@argenx.com
www.argenx.com

BMJ

BMJ Journals is a collection of more than 60 medical and allied science titles. They are published by BMJ, the global healthcare knowledge provider and pioneer in the development of open access. BMJ publishes Annals of the Rheumatic Diseases, the official journal of EULAR and one of the leading rheumatology journals. BMJ's rheumatology portfolio includes RMD Open, one of the most highly respected open access journals in the field with a Journal Impact Factor of 6.2 and CiteScore of 7.7. BMJ publishes Lupus Science & Medicine on behalf of the Lupus Foundation of America. LSM is the leading lupus-specific open access journal, with a Journal Impact Factor of 3.9 and a CiteScore of 5.

BMJ recently launched BMJ Impact Analytics, an analytics tool designed to track, and share the real-world impact of research on health and social care and provides clinical decision support and education resources to clinicians globally.



BMJ
BMA House
Tavistock Square
London WC1H 9JR
United Kingdom
www.bmj.com

CABALETTA BIO

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative responses for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody receptor T cells). The lead CARTA product candidate is CABA-201, a 4-1BB-containing fully human CD19-CAR T, being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trial program which is actively enrolling two Phase 1/2 rheumatology trials in patients with SLE and myositis in addition to ramping up two IND-cleared Phase 1/2 trials in systemic sclerosis and generalized myasthenia gravis. The CAART strategy is actively enrolling patients in a pemphigus vulgaris trial and a MuSK myasthenia gravis trial, including evaluation of various preconditioning regimens. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA.

Cabaletta Bio®

Cabaletta Bio, Inc.
2929 Arch Street, Suite 600,
Philadelphia, PA 19104
United States of America
Tel: +1 267-759-3100
contactus@cabalettabio.com
www.cabalettabio.com

CESAS MEDICAL

The Lupus Forum is an academically led, independent, educational platform aimed at healthcare professionals involved in the treatment of lupus. Overseen by a global Steering Committee, chaired by Professor Edward Vital, the Lupus Forum delivers a range of resources, from reviews of key papers to key congress coverage, to keep members up-to-date with the latest in lupus research.

The Immune-Mediated Inflammatory Disease Forum, previously known as The Cytokine Signalling Forum (CSF), is dedicated to the dissemination of the latest developments in immune-mediated inflammatory diseases. Overseen by an expert Steering Committee lead by Professor Iain McInnes, the forum provides resources to clinicians around the globe via summary slides, podcasts, congress coverages, and webinars.



CESAS Medical
1, The Green,
Strafford, ST17 48H
United Kingdom
Tel: +44 1785 785 810

CLARIUS MOBILE HEALTH

High-Definition Wireless Ultrasound for Rheumatology

Clarius HD3 is the ideal wireless ultrasound scanner for high-resolution MSK imaging. Make a confident diagnosis and improve procedural safety with real-time imaging of joints, tendons, cartilage, and bone. Clear imaging helps to diagnose and differentiate inflammatory arthritis, even at early stages.

Image Clarity You Can Trust for a Confident Diagnosis
With 8 times the processing power of most handheld ultrasound systems, Clarius HD3 gives you high-resolution imaging of muscle and tissue to assess inflammatory changes and guide injections and aspirations with confidence. With AI assistance on your smart device, getting a great image is easy. Start scanning in seconds, then simply pinch to zoom, slide to change gain, and tap to switch modes.

- Confidently identify joint effusions
- Enhance diagnosis, expedite treatment, and improve clinical outcomes
- Evaluate and characterize rheumatoid nodules
- Guide articular and periarticular aspirations or injections
- Visualize subclinical changes such as synovitis, tenosynovitis, enthesitis, bone erosions, and crystal deposits
- Foster patient trust and commitment to your treatment plan



Clarius Mobile Health
9 Appold Street, 6th Floor
EC2A 2AP, London
United Kingdom
www.clarius.com

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Clinical and Experimental Rheumatology is a monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983. This monthly journal also includes annual monothematic issues on the following topics: Behçet's disease and other autoinflammatory conditions, Vasculitis, Scleroderma, Fibromyalgia and related syndromes, Sjögren's syndrome, and Myositis.

Clinical and Experimental
RHEUMATOLOGY

Clinical and Experimental
Rheumatology
via Santa Maria 31,
56126 Pisa,
Italy
www.clinexprheumatol.org

ESAOTE

Esaote is one of the world's leading producers of medical diagnostic solutions such as Ultrasound, its core business, Dedicated Magnetic Resonance as well as Healthcare Information Technology systems. Set up from scratch in the early 1980s, today Esaote is a truly global company and an ambassador of Made in Italy in the world. With headquarters in Genoa (Italy), it is now active in about 100 countries around the world.

Esaote offers an extended range of products specifically tuned to rheumatology applications and able to satisfy any clinical need. The ultrasound My Lab family boasts a complete range of Rheuma-dedicated systems, from portable to premium-end products. Be sure to stop by Esaote Booth S13 (Exhibition Hall B).



Esaote S.p.A.
Via E. Melen, 77
16152 Genoa – Italy
www.esaote.com

LABORATOIRES EXPANSCIENCE

We are convinced that aging and quality of life can be reconciled. This is why we help millions of individuals who suffer from osteoarthritis to continue doing what they love for as long as possible, by incarnating health that is committed to serving the greatest number. We design therapeutic solutions, we develop services that help patients take charge of their illness, and we are mobilized along with healthcare professionals and the society as a whole to improve prevention, diagnosis and compliance.

EXPANSCIENCE®

L A B O R A T O I R E S

Laboratoires Expanscience
1 place des saisons
92048 Paris La Défense Cedex
France
www.expanscience.com/en

GE HEALTHCARE

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an \$18 billion business with 51,000 employees working to create a world where healthcare has no limits.



GE HealthCare
Beethovenstrasse 239
42665 Solingen
Germany
www.gehealthcare.com

KYVERNA

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.

Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

By advancing more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.



Kyverna Therapeutics, Inc.
5980 Horton Street, Suite 550
Emeryville, CA 94608
www.kyvernmatx.com

LA LETTRE DU RHEUMATOLOGUE

La Lettre du Rhumatologue is a French monthly publication specialized in rheumatology. The editor in chief is Pr. Bernard Combe.

The publication is released in 4.000 copies issued 10 times a year.



La Lettre Du Rheumatologue
19-21, rue Dumont d'Urville
75116 Paris, France
Tel : +33 1 46 67 63 19
www.edimark.fr

MSD

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.



MSD
126 East Lincoln Avenue
P.O. Box 2000
Rahway, NJ 07065
United States of America
www.msd.com

NORDIC PHARMA

Nordic Pharma is a privately-owned international pharmaceutical company which focuses on the development and commercialization of specialty products to address unmet medical needs.

Nordic Pharma expertise relies on its own products, but also on partner products acquired at different stages of development. Its portfolio addresses needs in various therapeutic areas including Rheumatology, Dermatology, Ophthalmology, Women's health and Critical Care.

With the aim of being patient focused, and providing rheumatoid arthritis patients with devices adapted to their disease, Nordic Pharma conceived and developed its solution for injectable Methotrexate.

NORDiMET® Auto-injector and NORDiMET® in prefilled-syringes are indicated in active Rheumatoid Arthritis in adults, among other indications in rheumatology, gastroenterology and dermatology.

Nordic Pharma strives to bring innovative and efficient solutions to unmet medical needs, contributing to improved patient care.



Nordic Pharma
216, boulevard Saint-Germain
75007 Paris
www.nordicpharmagroup.com

REIG JOFRE

Reig Jofre is a Spanish pharmaceutical company, founded in 1929 and listed on the Spanish Stock Exchange market. The company is focused on research, development, manufacture and marketing of pharmaceutical products and food supplements.

Reig Jofre has 1,300 employees, 3 production centers in Europe, direct sales through our own affiliates in several countries in Europe (Spain, Portugal, France, Benelux, Poland, UK & Nordics) and 130 business partners in more than 70 countries around the world.

Reig Jofre Specialty Pharmacare Division has a strong portfolio in different therapeutical areas, in which the musculoskeletal segment can be highlighted. Reig Jofre has in the portfolio pharmaceuticals products for the osteoarthritis pain and food supplements for tendons and ligaments, among others.

All these products are very well supported with robust clinical studies showing its efficacy and safety. The products are marketed directly by Reig Jofre affiliates and by distributors partners with a great success sales record.



Reig Jofre
Gran Capita, 10 – 08970 Sant
Joan Despí,
Barcelona, Spain
Tel: +34 93 480 67 10
www.reigjofre.com

SANA BIOTECHNOLOGY

Sana Biotechnology, Inc. is a company focused on changing the possible for patients through engineered cells. Our most advanced programs include an allogeneic CAR T program for B-cell mediated autoimmune diseases (SC291), an allogeneic CAR T program targeting CD19+ cancers (SC291) an allogeneic CAR T program targeting CD22+ cancer (SC262), and a stem cell-derived pancreatic islet cell program for persons with type 1 diabetes (UP421).

SC291 is a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform. It has been shown that B cells drive disease pathology in many autoimmune diseases, and B-cell targeting therapies from several different modalities have been efficacious across multiple autoimmune diseases. Sana is currently recruiting a Phase 1 study evaluating SC291 in patients with multiple B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. For more information, please refer to our website and [ct.gov](https://www.ct.gov) (NCT06294236)



Sana Biotechnology
188 East Blaine Street
Suite 200
Seattle, WA 98120
United States of America
www.sana.com

SANOFI

ABOUT SANOFI

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

ABOUT REGENERON

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.



REGENERON

Sanofi
450 Waters Street
Cambridge MA 02141
United States of America
www.sanofi.com

TAKEDA

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.



Takeda Pharmaceutical Company
500 Kendall street
Cambridge, MA 02142
United States of America
www.takeda.com

THE JOURNAL OF RHEUMATOLOGY

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring peer-reviewed research articles on clinical subjects from scientists working in rheumatology and related fields, with the support of our esteemed Editorial Committee and Editorial Board. With over 1600 submissions a year from over 50 countries, each issue of The Journal of Rheumatology includes original clinical research articles, meta-analyses, editorials, historical vignettes, case reports, and letters by world-renowned experts studying drug therapy, patient-reported outcomes, discovery of therapeutic targets in the treatment of rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoarthritis, and other rheumatic and musculoskeletal diseases.



The Journal of Rheumatology
365 Bloor St., East., Ste. 9012
Toronto, ON M4W 3L4
Canada
www.jrheum.org

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Our complete blood test systems support the clinical diagnosis of allergy, asthma and autoimmune diseases. With 1,800 employees worldwide in ImmunoDiagnostics, we are a global leader in in-vitro allergy diagnostics and a European leader in autoimmunity diagnostics. The allergy and autoimmunity product lines operate on a common automated instrument platform, which supports both productivity and cost efficiencies in clinical laboratories around the world.

ThermoFisher
SCIENTIFIC

Thermo Fisher Scientific
168 Third Avenue
Waltham, MA 02451
United States of America
Tel; + 1-781-622-1000
www.thermofisher.com

VIATRIS

Viatis is a new company formed in November 2020 through the merger of two strong legacy companies (Mylan and Upjohn- the established business unit of Pfizer). The company has a diverse portfolio of over 1400 approved molecules including a portfolio of globally recognised iconic brands and a broad range of generic medicines.



At Viatis, we see healthcare not as it is but as it should be. We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs.

Viatis empowers people worldwide to live healthier at every stage of life through three pillars:

1. Access

Providing high-quality trusted medicines regardless of geography or circumstance

2. Leadership

Advancing sustainable operations and innovative solutions to improve patient health

3. Partnership

Leveraging our collective expertise to connect people to products and services.

Viatis
Robert J. Coury Global Center
1000 Mylan Blvd.
Canonsburg, PA 15317
United States of America
Tel: + 1-724-514-1800
www.viatis.com

WISEPRESS

Wisepress.com, Europe's leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.



Wisepress Medical Bookshop
15A London Rd
Maidstone ME16 8LY
United Kingdom
Phone: +44 20 8715 1812
bookshop@wisepress.com
www.wisepress.com

XIRALITE GMBH

Xiralite GmbH is a medical device company located in the heart of Berlin, Germany. We offer innovative concepts for the diagnosis and therapy of several diseases, thereby providing significantly improved benefits to our customers. Xiralite's key technology is based on fluorescence optical imaging and our medical imaging devices enable diagnostics of microcirculation disorders. Through this unique technology, alterations of the microcirculation become visible allowing for the identification of different types of rheumatic diseases. Our devices are installed worldwide in clinical practices, hospitals and research institutions.



Xiralite GmbH
Luisencarrée
Robert-Koch-Platz 4
10115 Berlin
Germany
Phone: +49 (0)30.890 49 74 - 31
www.xiralite.com

ZENAS BIOPHARMA

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies for patients in need around the world. Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our portfolio consists of several clinical stage product candidates focused on treating autoimmune disorders such as IgG4-RD, wAIHA, Systemic Lupus Erythematosus (SLE) and other disease states not yet disclosed. We are excited to partner with the rheumatology community to advance the scientific understanding of these important disease states.



Zenas BioPharma
1000 Winter St
North Building, Suite 1200
Waltham, MA 02451
United States of America
www.zenasbio.com



eular²⁵

EUROPEAN
CONGRESS OF
RHEUMATOLOGY

BARCELONA
11–14 JUNE

SEE YOU
2025 IN
BARCELONA

congress.eular.org

congress.eular.org

EULAR Office
Seestrasse 240
8802 Kilchberg
Switzerland

EULAR ©